Edition:
United States

MDxHealth SA (MDXH.BR)

MDXH.BR on Brussels Stock Exchange

5.14EUR
24 Mar 2017
Change (% chg)

€-0.19 (-3.66%)
Prev Close
€5.34
Open
€5.32
Day's High
€5.33
Day's Low
€5.13
Volume
242,325
Avg. Vol
198,126
52-wk High
€5.78
52-wk Low
€2.87

Latest Key Developments (Source: Significant Developments)

MDxHealth signs agreement with Lab21 to make SelectMDX available in UK
Tuesday, 21 Mar 2017 02:01am EDT 

MDxHealth SA :Signs agreement with Lab21 to make SelectMDX liquid biopsy test available in the United Kingdom.  Full Article

MDxHealth: SelectMDx chosen by Michigan Medicine
Wednesday, 8 Mar 2017 01:00am EST 

MDxHealth SA :Reg-SelectMDx chosen by Michigan Medicine as pre-biopsy diagnostic tool in groundbreaking us prostate cancer risk clinic.  Full Article

Mdxhealth signs agreement for distribution of SelectMDx throughout Central-South Italy
Thursday, 23 Feb 2017 01:05am EST 

Mdxhealth SA :Signs distribution deal to make its selectMDx for prostate cancer test available to Istituto Diagnostico Varelli's urology clients throughout Central-South Italy.  Full Article

MDxHealth cash position at year end $30.9 mln
Thursday, 23 Feb 2017 01:00am EST 

MDxHealth SA : Reports FY revenue of $30 million, up 70 pct from 2015 . FY EBITDA loss of $11.1 million improved by $2.5 million from 2015 . Cash and cash equivalents of $30.9 million, at December 31, 2016 . Sees growth between 55-75 pct on product and service income, excluding royalties and milestone payments in 2017 .Maintaining focus on its strategic priorities during 2017.  Full Article

MDxHealth awarded ConfirmMDx testing contract by US VA
Wednesday, 8 Feb 2017 01:00am EST 

MDxHealth SA :MDxHealth awarded US department of Veterans Affairs (VA) contract for ConfirmMDx testing.  Full Article

MDxHealth expects to achieve upgraded guidance for FY 2016 and appoints new CFO
Monday, 9 Jan 2017 01:00am EST 

MDxHealth SA : MDxHealth announces preliminary update on 2016 results and appointment of CFO . Expects to achieve upgraded market guidance for FY 2016 financial results following continued strong growth of ConfirmMDx and early adoption of SelectMDx during year . Underlying earnings before interest, taxes, depreciation and amortization (ebidta) are also expected to improve compared to 2015 . Full-Year 2016 results will reflect initial sales of company's SelectMDx for prostate cancer "liquid biopsy" test . Co previously upgraded its expected full-year revenue growth to more than 60 percent compared with its initial guidance predicting growth of 30-50 percent over 2015 .MDxHealth announces appointment of Jean-Marc Roelandt as chief financial officer with effect from January 15, 2017.  Full Article

MDxHealth signs distribution agreement with SouthGenetics
Tuesday, 4 Oct 2016 01:00am EDT 

MDxHealth SA :Announces agreement with SouthGenetics for distribution of SelectMDx in Central and South America.  Full Article

MDxHealth signs distribution agreement in Poland
Wednesday, 28 Sep 2016 01:00am EDT 

MDxHealth SA :MDxHealth and the European Health Centre Innovation sign distribution agreement for SelectMDx and ConfirmMDx in Poland.  Full Article

MDxHealth announces upgraded revenue forecast
Thursday, 22 Sep 2016 01:00am EDT 

MDxHealth SA : MDxHealth announces upgraded revenue forecast . Revenue for year is expected to exhibit growth of more than 60 pct over previous year, compared with prior guidance predicting growth of 30-50 pct . Company maintains its guidance that underlying earnings before interest, taxes, depreciation and amortization (EBIDTA) for year ended 2016 are expected to improve compared to 2015 .Improved performance since the Company's last update can be attributed to accelerated adoption of the Company's ConfirmMDx for prostate cancer test by Urologists in the U.S..  Full Article

MDxHealth gets Medi-Cal Approval for ConfirmMDx
Tuesday, 6 Sep 2016 01:22am EDT 

Mdxhealth SA :Announced that ConfirmMDx for prostate cancer test is now available as an in-network benefit under California Medical Assistance Program (Medi-Cal).  Full Article

More From Around the Web

BRIEF-MDxHealth signs agreement with Lab21 to make SelectMDX available in UK

* Signs agreement with Lab21 to make SelectMDX liquid biopsy test available in the United Kingdom Source text for Eikon: Further company coverage: (Gdynia Newsroom)